IDEXX Laboratories/$IDXX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
- Ticker
- $IDXX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11,000
- Headquarters
- Westbrook, United States
- Website
- www.idexx.com
IDXX Metrics
BasicAdvanced
$44B
39.40
$14.22
1.55
-
Price and volume
Market cap
$44B
Beta
1.55
52-week high
$769.98
52-week low
$500.61
Average daily volume
514K
Financial strength
Current ratio
1.172
Quick ratio
0.729
Long term debt to equity
0.186
Total debt to equity
0.68
Interest coverage (TTM)
38.84%
Profitability
EBITDA (TTM)
1,612.685
Gross margin (TTM)
62.45%
Net profit margin (TTM)
25.03%
Operating margin (TTM)
32.23%
Effective tax rate (TTM)
19.99%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
27.09%
Return on equity (TTM)
74.21%
Valuation
Price to earnings (TTM)
39.4
Price to revenue (TTM)
9.802
Price to book
27.41
Price to tangible book (TTM)
27.41
Price to free cash flow (TTM)
36.078
Free cash flow yield (TTM)
2.77%
Free cash flow per share (TTM)
15.533
Growth
Revenue change (TTM)
12.77%
Earnings per share change (TTM)
18.41%
3-year revenue growth (CAGR)
9.02%
10-year revenue growth (CAGR)
10.42%
3-year earnings per share growth (CAGR)
14.67%
10-year earnings per share growth (CAGR)
20.49%
What the Analysts think about IDXX
Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.
Analyst projections of the future price of IDEXX Laboratories stock.
Bulls say / Bears say
IDEXX’s recurring diagnostics business continues to grow quickly: it delivered 10% organic growth in Q2, with higher testing volumes and customer gains, and the company raised its 2026 organic revenue outlook. This suggests its consumables and laboratory model can keep growing even when clinic traffic is soft. (IDEXX Laboratories)
New tests and instruments give IDEXX room to win more diagnostic work from each practice. Its inVue Dx installed base exceeded 9,000 instruments in Q2, while the new Catalyst proBNP test adds cardiac testing to a global base of nearly 80,000 Catalyst analysers. (IDEXX Laboratories, IDEXX Laboratories)
Profit growth is running ahead of sales: Q2 comparable EPS rose 15% and comparable operating margin expanded by 110 basis points. IDEXX also raised its 2026 EPS outlook, pointing to continued scope for operating leverage. (IDEXX Laboratories)
Weak clinic traffic remains a constraint, especially for discretionary wellness care. US same-store clinical visits fell 1.3% in Q2, with wellness visits down 3.4%, and management expected visits to decline again in the second half. (The Motley Fool, Stock Analysis)
Not every product line is advancing at the same pace: Q2 capital instrument revenue fell 20% organically, while rapid assay revenue grew only 1%. Continued weakness in equipment placements or shifts between testing methods could weigh on growth in these lines. (IDEXX Laboratories)
The shares carried a demanding valuation in July, at about 38 times 2026 earnings guidance and a free-cash-flow yield near 2.5%, according to Seeking Alpha. That leaves less room for an earnings or guidance setback before the valuation comes under pressure. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 24 Oct 2026.
IDXX Financial Performance
Revenues and expenses
IDXX Earnings Performance
Company profitability
Upcoming events
No upcoming events
IDXX News
AllArticlesVideos
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
Business Wire3 weeks ago
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
MarketBeat1 month ago
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
MarketBeat1 month ago
Funds containing IDXX
AllUSDEURGBP
Fund name | Fund size | $IDXX weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.65% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.65% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.70% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.70% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.68% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.